These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26814180)

  • 1. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
    Behroozian S; Svensson SL; Davies J
    mBio; 2016 Jan; 7(1):e01842-15. PubMed ID: 26814180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
    Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
    Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity.
    Zhanel GG; Karlowsky JA
    mBio; 2016 Mar; 7(2):e00169. PubMed ID: 26956585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad-Spectrum Antimicrobial and Antibiofilm Activity of a Natural Clay Mineral from British Columbia, Canada.
    Behroozian S; Svensson SL; Li LY; Davies JE
    mBio; 2020 Oct; 11(5):. PubMed ID: 33024043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens.
    Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M
    Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens.
    Haydel SE; Remenih CM; Williams LB
    J Antimicrob Chemother; 2008 Feb; 61(2):353-61. PubMed ID: 18070832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico.
    Llaca-Díaz JM; Mendoza-Olazarán S; Camacho-Ortiz A; Flores S; Garza-González E
    Chemotherapy; 2012; 58(6):475-81. PubMed ID: 23548324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kisameet Glacial Clay: an Unexpected Source of Bacterial Diversity.
    Svensson SL; Behroozian S; Xu W; Surette MG; Li L; Davies J
    mBio; 2017 May; 8(3):. PubMed ID: 28536287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
    Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
    [No Abstract]   [Full Text] [Related]  

  • 11. [Analysis of distribution and drug resistance of pathogens of burn patients during 9 years].
    Dou Y; Zhang Q
    Zhonghua Shao Shang Za Zhi; 2018 Mar; 34(3):153-159. PubMed ID: 29609277
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens.
    Hijazi S; Visaggio D; Pirolo M; Frangipani E; Bernstein L; Visca P
    Front Cell Infect Microbiol; 2018; 8():316. PubMed ID: 30250828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-drug resistant ESKAPE pathogens and the uses of plants as their antimicrobial agents.
    Idris FN; Nadzir MM
    Arch Microbiol; 2023 Mar; 205(4):115. PubMed ID: 36917278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of the ESKAPE pathogens.
    Pendleton JN; Gorman SP; Gilmore BF
    Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections.
    Younis W; Thangamani S; Seleem MN
    Curr Pharm Des; 2015; 21(28):4106-11. PubMed ID: 25961308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance patterns among nosocomial pathogens: trends over the past few years.
    Jones RN
    Chest; 2001 Feb; 119(2 Suppl):397S-404S. PubMed ID: 11171776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and challenges in implementing the research on ESKAPE pathogens.
    Rice LB
    Infect Control Hosp Epidemiol; 2010 Nov; 31 Suppl 1():S7-10. PubMed ID: 20929376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
    Tiwari V; Meena K; Tiwari M
    Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.